Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC Crescendo expands trial of lead programme first-in-class, bispecific...
Crescendo Biologics Ltd., a clinical stage immuno-oncology company developing targeted T cell enhancing therapeutics, plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured to fund the combination expansion arm of the adaptive clinical protocol, with support of all major existing shareholders, including Sofinnova Partners, Andera Partners, IP Group BioNTech, Takeda and Quan Capital, and new investor Kreos Capital.
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
Angle PLC, a liquid biopsy company, has signed a contract with Crescendo Biologics Limited, a UK-based, clinical stage immuno-oncology company with an extensive pipeline of novel, targeted T cell enhancing Humabody therapeutics.
BioNTech will provide the upfront fee to the Cambridge, U.K.-based biotech and a potential $750 million in biobucks for immunotherapies against cancer and other undisclosed diseases. The biotech, emboldened and lined with cash from its pandemic vaccine, will choose the targets for the mRNA-based antibodies and engineered cell therapies, the company said on the first day of the annual J.P. Morgan Healthcare Conference.
Scientists at The Institute of Cancer Research, London, are working with the Cambridge-based immuno-oncology company Crescendo Biologics on its development of a potential ‘next generation’ immunotherapy.
CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has reported positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody®.
CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces a new translational science collaboration with The Institute of Cancer Research, London, one of the world’s most influential cancer research organisations. Working together, Crescendo and The Institute of Cancer Research (ICR) will further characterise the non-clinical pharmacology of CB307, Crescendo’s first-in-class lead programme.
Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events. They look forward to meeting investors to discuss the Company’s business strategy, technology, discovery platform and development programmes.